ImmunityBio Crashes On FDA Warning Over Anktiva Claims

ImmunityBio, Inc. (NASDAQ:IBRX) shares are trading lower after the FDA issued a warning to the company over misleading Anktiva promotions.ImmunityBio stock is feeling bearish pressure. What’s pressuring IBRX stock?FDA Flags Misleading Promotional ClaimsThe U.S. Food and Drug Administration determined that a direct-to-consumer TV ad and podcast promoting Anktiva were false or misleading and misbranded the drug under federal law. The FDA said the materials made unsupported claims that Anktiva could cure or pr ...